Management regimes in science-based innovation: control and uncertainty during early phases of new drug development
Artikel i vetenskaplig tidskrift, 2011
The international pharmaceutical industry is facing a challenge in terms of being able to deliver new and innovative drugs at lower cost. During the last 10 years, a range of new scientific procedures and technologies has been introduced into the industry, partially derived from the advancement of genomics research. However, to date, few have resulted in new registered drugs. In addition to the new technologies, various managerial techniques and methods have been introduced with the intention of increasing the transparency of operations. This paper reports on a study of how scientists during the early phases of new drug development conceive of this present management regime emphasising quantitative output. Thinking of new drug development as an intellectual pursuit in order to understand the elementary mechanisms of the biological organisms on the molecular level, scientists call for an understanding and adjustment of the managerial techniques structuring this work, accompanied by ambiguities and uncertainty.
networks
adaptation
identity
management regime
innovation
biotechnology
mindfulness
new drug development
organizational routines
knowledge
creativity
product-innovation
science-based
performance
pharmaceutical industry
Författare
Alexander Styhre
Chalmers, Teknikens ekonomi och organisation
M. Sundgren
AstraZeneca AB
Technology Analysis and Strategic Management
0953-7325 (ISSN) 1465-3990 (eISSN)
Vol. 23 5 567-581Ämneskategorier
Produktionsteknik, arbetsvetenskap och ergonomi
DOI
10.1080/09537325.2011.565671